Infarmed, the national medicines authority, has withdrawn a batch of the medication Salofalk from the market. The decision was communicated through a circular published today on the entity's official website.
The batch in question is L25428A, with expiry until November 2029. The medication Salofalk is used in the treatment of intestinal inflammation.
The regulatory authority did not specify the reasons that led to the withdrawal of the batch from the market in this communication. The information was made available to the public through an official statement.




